Gene therapy and solid-organ transplantation

Kidney International

Volumn 61, Issue SUPPL. 1, 2002, Pages

  Akalin, Enver ^a   Bromberg, Jonathan S ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Allograft; Gene therapy; Rejection; Transplantation; Xenotransplantation

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND MONOCLONAL ANTIBODY; COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

ALLOIMMUNITY; ANTIBODY PRODUCTION; APOPTOSIS; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SURVIVAL; XENOTRANSPLANTATION;

EID: 0036175802     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.0610s1056.x     Document Type: Conference Paper

References (43)

1. Improved graft survival after renal transplantation in the United States, 1988 to 1996
2. Long-term survival in renal transplant recipients with graft function
3. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection
4. Gene transfer to facilitate transplantation
5. T cell costimulatory blockade: New therapies for transplant rejection
6. The thymic way to transplantation tolerance
7. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes
8. Pretransplant administration of a single donor class I major histocompatibility complex molecule is sufficient for the indefinitive survival of fully allogenic cardiac allografts: Evidence for linked epitope suppression
9. Specific prolongation of skin graft survival following retroviral transduction of bone marrow with an allogenic major histocompatibility complex gene
10. Expression of an allogenic MHC DRB transgene, through retroviral transduction of bone marrow, induces specific reduction of alloreactivity
11. Effective use of donor MHC class I gene therapy in organ transplantation: Prevention of antibody-mediated hyperacute heart allograft rejection in highly sensitized rat recipients
12. Adenovirus-mediated gene transfer into cold-preserved liver allografts: Survival pattern and unresponsiveness following transduction with CTLA4Ig
13. Cardiac allograft tolerance induced by intra-arterial infusion of recombinant adenoviral CTLA4Ig
14. Improved survival of biolistically transfected mouse islet allografts expressing CTLA4Ig or soluble fas ligand
15. CD28-B7 blockade after alloantigen challenge in vivo inhibits Th1 cytokines but spares Th2
16. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model: Immunosuppression with TGFβ1 or vIL-10
17. Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival
18. Intracoronary adenovirus-mediated transfer of immunosuppressive cytokine genes prolongs allograft survival
19. Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses
20. Gene transfer of transforming growth factor-beta 1 prolongs murine cardiac allograft survival by inhibiting cell-mediated immunity
21. Adenovirus-mediated gene transfer in the transplant setting: Early events after orthotopic transplantation of liver allografts expressing TGF-beta 1
22. Interleukin-10 produced by recombinant adenovirus prolongs survival of cardiac allografts in rats
23. Chemokines and their receptors in allograft rejection
24. Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity
25. Fas ligand gene transfer to renal allografts in rats: Effects on allograft survival
26. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid
27. Accelerated rejection of Fas ligand-expressing heart grafts
28. Immunologic ignorance of vascularized organ transplants in the absence of secondary lymphoid tissue
29. Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogenic recipients
30. Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappaB activation
31. Genetic modification of liver grafts with an adenoviral vector encoding the bcl-2 gene improves organ preservation
32. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes
33. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene
34. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis
35. Ex vivo gene therapy prevents chronic graft vascular disease in cardiac allografts
36. Optimization of ex vivo pressure mediated delivery of antisense oligodeoxynucleotides to ICAM-1 reduces reperfusion injury in rat cardiac allografts
37. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide
38. Inhibition of xenoreactive natural antibody production by retroviral gene therapy
39. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury
40. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors
41. Orthotopic heart transplantation in a transgenic pig-to-primate model
42. Life-supporting pig-to-baboon heart xenotransplantation
43. Potential use of genetically modified pigs as organ donors for transplantation into humans